Posted by Michael Wonder on 06 Oct 2018
AbbVie receives Health Canada approval of Orilissa (elagolix) for the treatment of moderate to severe pain associated with endometriosis
5 October 2018 - The approval of Orilissa is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women.
AbbVie, in cooperation with Neurocrine Biosciences, announced that Health Canada approved Orilissa (elagolix), the first and only oral gonadotropin-releasing hormone receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis.
The approval of Orilissa is supported by data from two replicate studies in the largest endometriosis Phase 3 study program conducted to date, which evaluated nearly 1,700 women with moderate to severe endometriosis pain.
